A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 137 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-18.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is one of 9 that started in 2009, is one of 47 in phase 3, and was the 35th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Keio University · Sites in Japan
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Konkuk University Medical Center · Sites in Korea, Republic of
Ages 19+
Medical University of Vienna · Sites in Austria
Ages 18–99
By country, each count listing its studies:
Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 48 · Phase 4 38
First in 1998; this study’s year is marked. 9 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 556 is above the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 130 across the 113 interventional studies. Of the 93 that completed or were terminated, 58 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
84 of 113 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 22nd largest by enrollment of the 141 interventional ones that give a count, is one of 22 that started in 2009, is one of 85 in phase 3, and was the 55th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
3 of the studies testing methotrexate in Arthritis, Rheumatoid that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05353829Region VästerbottenMethotrexate in Patients with Early Rheumatoid Arthritis | 2026-12-31 |
| NCT06590090XBiotech, Inc.Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment | 2027-01-15 |
| NCT06649136Medical University of ViennaMethMax Trial: MAXimising the METHotrexate Therapy Potential in Patients With Active Rheumatoid Arthritis | 2027-06-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis. Patients receiving methotrexate treatment will be randomized to receive either a) tocilizumab 8 mg intravenous (iv) every 4 weeks + methotrexate orally (po) weekly or b) tocilizumab 8 mg iv every 4 weeks + placebo po weekly. After the first 24 weeks of blinded treatment, treatment adjustments (increase or decrease of treatment intensity) may be introduced at intervals, based on response. The anticipated time on study treatment is up to 3 years, and the target sample size is approximately 470 patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.
Drug: tocilizumab [RoActemra/Actemra] · Drug: methotrexate
Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.
Drug: tocilizumab [RoActemra/Actemra] · Drug: placebo
Drug page: Tocilizumab
tocilizumab 8 mg IV every 4 weeks.
Also known as: RoActemra/Actemra
Approximately 15-17 mg methotrexate capsule orally once a week.
Placebo matching methotrexate capsule taken orally once a week.
Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Week 24
Percentage of Participants With American College of Rheumatology (ACR20) Response
ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Baseline, Weeks 24, 52, 104
Percentage of Participants With ACR50 Response
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Baseline, Weeks 24, 52, 104
Percentage of Participants With ACR70 Response
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Baseline, Weeks 24, 52, 104
Percentage of Participants With ACR90 Response
ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: Baseline, Weeks 24, 52, 104
Time to First ACR20 Response
Time in days from first administration of study drug until ACR20 response. ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: 104 Weeks
Time to First ACR50 Response
Time in days from first administration of study drug until ACR50 response. ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate).
Time frame: 104 Weeks
Time to First ACR70 Response
Time in days from first administration of study drug until ACR70 response. ACR70 response is defined as a ≥ 70% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: 104 Weeks
Time to First ACR90 Response
Time in days from first administration of study drug until ACR90 response. ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
Time frame: 104 Weeks
Area Under Curve (AUC) DAS28
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. AUC DAS28 was averaged over study days. Analysis of Covariance was adjusted for Baseline DAS28 as a covariate and treatment group and region as fixed factors. Higher calculated AUC values are worse (indicate higher disease activity).
Time frame: Baseline to Week 24
Percentage of Participants With Disease Activity Score 28 (DAS28) Remission
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
Time frame: Week 52
Percentage of Participants With DAS28 Low Disease Activity (LDAS)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2.
Time frame: Weeks 24, 52
Change From Baseline in DAS28 Score
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A higher value indicated higher disease activity. A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 24, 52
Percentage of Participants With Good or Moderate European League (EULAR) DAS28 Responses
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. European League Against Rheumatism (EULAR) Good response: DAS28 ≤ 3.2 or a change from Baseline \< -1.2. EULAR Moderate response: DAS28 \> 3.2 to ≤ 5.1 or a change from Baseline \< -0.6 to ≥ -1.2.
Time frame: Baseline, 24, 52
Change From Baseline in Swollen Joint Count
66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 24, 52
Change From Baseline in Tender Joint Count
68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 24, 52
Change From Baseline in Patient Global Assessment of Disease Activity Visual Analog Scale (VAS)
The patients global assessment of disease activity was assessed on a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 24, 52
Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale (VAS)
The physician global assessment of disease activity was assessed using a 0 to 100 mm horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 24, 52
Change From Baseline in Patient Global Assessment of Pain (VAS)
The patient assessed their pain using a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 24, 52
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Blood was collected for Erythrocyte Sedimentation Rate (ESR) (a test that assesses tissue inflammation) and was analyzed at a local laboratory. ESR was measured in millimeters/hour (mm/hr). A reduction in the level is considered an improvement.
Time frame: Baseline, Weeks 24, 52
Change From Baseline in C-Reactive Protein (CRP)
Blood was collected for C-Reactive Protein (CRP) (a test for analysis of inflammatory and infectious disorders) and was analyzed at a central laboratory. The serum concentration of CRP was measured in milligrams/deciliter (mg/dL). A reduction in the level is considered an improvement.
Time frame: Baseline, Weeks 24, 52
Change From Baseline in the Health Assessment Questionnaire Disability Index
The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis, consisting of 20 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. There are 4 possible responses for each question: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. The score for each of the domains is the highest (worst) score in each domain. A patient must have a domain score for at least 6 of 8 domains to calculate a valid HAQ-DI score which is the sum of domain scores, divided by the number of domains that have a score for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 24, 52
Change From Baseline in Total Genant Modified Sharp Scores (GSS)
Radiographs were taken of each hand and foot at Baseline, Weeks 24, 52 and104 and were evaluated using the Genant modified method according to Sharp. Erosion Score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. Joint Narrowing Score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). The maximum total erosion score in the hands is 98 and in the feet 42. The maximum scores for joint space narrowing (JSN) in the hands was104 and in the feet 48. The total score was the sum of scores for erosions and JSN. The maximum total modified GSS was 292. A lower number change from Baseline was better. Analysis of covariance model, with Baseline DAS28 as a covariate and treatment and site as fixed factors.
Time frame: Baseline, Weeks 24, 52, 104
Change From Baseline in Joint Space Narrowing Score
A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). The maximum scores for joint space narrowing (JSN) in the hands was 104 and in the feet 48 for a total possible score of 0 to 152. A lower change from Baseline indicated a better score. Analysis of covariance model included baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.
Time frame: Baseline, Weeks 24, 52, 104
Change From Baseline in Erosion Score
A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. The maximum erosion score in the hands was 98 and in the feet 42 for a total possible score of 0 to 140. A lower number change from Baseline indicated a better score.
Time frame: Baseline, Weeks 24, 52, 104
Percentage of Participants Discontinuing Tocilizumab Due to Remission
The percentage of participants who stopped treatment with tocilizumab due to remission.
Time frame: Weeks 52, 104
Percentage of Participants Who Withdrew Due to Lack of Sufficient Therapeutic Response
Lack of Sufficient Therapeutic Response was defined as the patient not responding to the drug as expected.
Time frame: Up to 3 years
Percentage of Participants Who Withdrew Due to Safety Reasons
Safety reasons were defined as adverse events, intercurrent illness or death. An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
Time frame: Up to 3 years
Change From Baseline in Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL)
The RAQoL is a disease specific patient-reported outcome measure that determines the effect rheumatoid arthritis has on a patient's quality of life consisting of 30 questions that are answered either yes=1 or no=0 for a total possible score ranging from 0 (best) to 30 (worst). A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 24, 52, 104
Change From Baseline in Academic Medical Center (AMC) Linear Disability Scale (ALDS)
The Academic Medical Center (AMC) Linear Disability Score (ALDS) evaluates the participant's ability to perform activities of daily life consisting of 77 questions answered yes or no . The question difficulty and the patient's ability are arranged on a single hierarchical linear scale. ALDS scores range from 10 to 90 with a higher score representing higher functional status. A positive change from Baseline indicated improvement.
Time frame: Baseline, Weeks 104
Area Under the Curve (AUC) From Baseline to Week 24 for ACR Response
ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]. Area under the curve for ACR response to Week 24 was averaged over study days. Analysis of covariance model includes treatment group, region and baseline DAS28 (≤ 5.5 and \> 5.5) as fixed factors.
Time frame: Baseline to Week 24
Area Under the Curve (AUC) From Baseline to Week 52 for ACR Response
ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].Area under the curve for ACR response to Week 52 averaged over study days. Analysis of covariance model includes treatment group, region and baseline DAS28 (\<=5.5 and \>5.5) as fixed factors.
Time frame: Baseline to Week 52
Time to Tocilizumab Remission
The time in days from initial study drug treatment to tocilizumab remission that occurred when the patient discontinued treatment with tocilizumab.
Time frame: 104 Weeks
Time to Drug-Free Remission
The time in days from initial study drug treatment to drug free remission that occurred when the participant was able to discontinue tocilizumab, methotrexate/placebo and open label disease-modifying antirheumatic drugs (DMARDS).
Time frame: 104 Weeks
Time to Flare After Tocilizumab Remission
The time in days to a flare (recurrence of disease symptoms) after the patient discontinued treatment with tocilizumab.
Time frame: 104 Weeks
Time to Restart of Treatment After Discontinuation/Remission
The time in days from treatment discontinuation or remission to the restart of treatment.
Time frame: 104 Weeks
| Milestone | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Started | 279 | 277 |
| Received study drug | 277 | 276 |
| Completed week 24 | 259 | 250 |
| Completed week 52 | 243 | 229 |
| Completed week 104 | 222 | 201 |
| Completed | 220 | 195 |
| Not completed | 59 | 82 |
| Withdrew: Adverse event | 24 | 26 |
| Withdrew: Death | 4 | 6 |
| Withdrew: Withdrew consent | 9 | 12 |
| Withdrew: Insufficient therapeutic response | 5 | 14 |
| Withdrew: Refused treatment/did not cooperate | 7 | 7 |
| Withdrew: Administrative/other | 5 | 6 |
| Withdrew: Protocol violation | 2 | 6 |
| Withdrew: Failure to return | 1 | 4 |
| Withdrew: Did not receive study drug | 2 | 1 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24 | 40.4 | 34.8 |
ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 | 71.5 | 70.3 |
| Week 52 | 70.8 | 69.2 |
| Week 104 | 65.7 | 59.4 |
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 | 45.5 | 40.2 |
| Week 52 | 50.2 | 55.4 |
| Week 104 | 52.7 | 46.4 |
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 | 24.5 | 25.4 |
| Week 52 | 31.4 | 31.2 |
| Week 104 | 34.3 | 29.3 |
ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 | 5.8 | 5.1 |
| Week 52 | 12.6 | 11.2 |
| Week 104 | 11.9 | 9.1 |
Time in days from first administration of study drug until ACR20 response. ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Days | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Time to First ACR20 Response | 57.0 (NA to NA) | 61.0 (57.0 to 84.0) |
Time in days from first administration of study drug until ACR50 response. ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate).
| Days | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Time to First ACR50 Response | 140.0 (113.0 to 142.0) | 143.0 (137.0 to 169.0) |
Time in days from first administration of study drug until ACR70 response. ACR70 response is defined as a ≥ 70% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Days | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Time to First ACR70 Response | 284.0 (225.0 to 327.0) | 307.0 (253.0 to 338.0) |
Time in days from first administration of study drug until ACR90 response. ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].
| Days | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Time to First ACR90 Response | NA (844.0 to NA) | NA (986.0 to NA) |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. AUC DAS28 was averaged over study days. Analysis of Covariance was adjusted for Baseline DAS28 as a covariate and treatment group and region as fixed factors. Higher calculated AUC values are worse (indicate higher disease activity).
| Score on a scale*week | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Area Under Curve (AUC) DAS28 | 3.97 ± 0.098 | 4.23 ± 0.092 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Percentage of Participants With Disease Activity Score 28 (DAS28) Remission | 45.5 | 36.6 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2.
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 | 61.7 | 51.4 |
| Week 52 | 62.5 | 57.2 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A higher value indicated higher disease activity. A negative change from Baseline indicated improvement.
| Score on a scale | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 | -3.43 ± 1.326 | -3.21 ± 1.305 |
| Week 52 | -3.74 ± 1.406 | -3.67 ± 1.291 |
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. European League Against Rheumatism (EULAR) Good response: DAS28 ≤ 3.2 or a change from Baseline \< -1.2. EULAR Moderate response: DAS28 \> 3.2 to ≤ 5.1 or a change from Baseline \< -0.6 to ≥ -1.2.
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 | 89.5 | 86.2 |
| Week 52 | 84.5 | 78.2 |
66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.
| Joint count | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n=255,246) | -11.33 ± 8.042 | -11.74 ± 9.446 |
| Week 52 (n=237,220) | -12.29 ± 8.796 | -12.25 ± 8.949 |
68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.
| Joint count | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n=255,246) | -17.27 ± 13.358 | -17.00 ± 13.632 |
| Week 52 (n=237,220) | -19.45 ± 13.471 | -18.97 ± 12.768 |
The patients global assessment of disease activity was assessed on a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
| mm | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n=255,246) | -34.31 ± 25.677 | -32.42 ± 24.344 |
| Week 52 (n=239,220) | -38.92 ± 25.590 | -40.94 ± 26.211 |
The physician global assessment of disease activity was assessed using a 0 to 100 mm horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
| mm | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n=249,244) | -40.67 ± 19.500 | -38.46 ± 21.654 |
| Week 52 (n=232,218) | -44.18 ± 21.092 | -44.68 ± 21.400 |
The patient assessed their pain using a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change from Baseline indicated improvement.
| mm | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n=255,246) | -29.34 ± 26.639 | -29.75 ± 24.918 |
| Week 52 (239,220) | -33.09 ± 26.933 | -38.38 ± 25.537 |
Blood was collected for Erythrocyte Sedimentation Rate (ESR) (a test that assesses tissue inflammation) and was analyzed at a local laboratory. ESR was measured in millimeters/hour (mm/hr). A reduction in the level is considered an improvement.
| mm/hr | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n=255,246) | -30.61 ± 24.187 | -29.10 ± 24.518 |
| Week 52 (n=238,220) | -31.81 ± 23.025 | -31.18 ± 24.527 |
Blood was collected for C-Reactive Protein (CRP) (a test for analysis of inflammatory and infectious disorders) and was analyzed at a central laboratory. The serum concentration of CRP was measured in milligrams/deciliter (mg/dL). A reduction in the level is considered an improvement.
| mg/dL | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n=252,241) | -1.37 ± 2.043 | -1.39 ± 2.206 |
| Week 52 (n=236,221) | -1.39 ± 1.943 | -1.40 ± 2.216 |
The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis, consisting of 20 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. There are 4 possible responses for each question: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. The score for each of the domains is the highest (worst) score in each domain. A patient must have a domain score for at least 6 of 8 domains to calculate a valid HAQ-DI score which is the sum of domain scores, divided by the number of domains that have a score for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from Baseline indicated improvement.
| Score on a scale | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n=251,241) | -0.56 ± 0.666 | -0.55 ± 0.531 |
| Week 52 (n=235,213) | -0.59 ± 0.713 | -0.67 ± 0.630 |
Radiographs were taken of each hand and foot at Baseline, Weeks 24, 52 and104 and were evaluated using the Genant modified method according to Sharp. Erosion Score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. Joint Narrowing Score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). The maximum total erosion score in the hands is 98 and in the feet 42. The maximum scores for joint space narrowing (JSN) in the hands was104 and in the feet 48. The total score was the sum of scores for erosions and JSN. The maximum total modified GSS was 292. A lower number change from Baseline was better. Analysis of covariance model, with Baseline DAS28 as a covariate and treatment and site as fixed factors.
| Score on a scale | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n= 266,258) | 0.18 ± 0.161 | 0.35 ± 0.152 |
| Week 52 (n= 269,264) | 0.35 ± 0.370 | 0.63 ± 0.350 |
| Week 104 (n= 215,202) | 0.35 ± 0.347 | 0.95 ± 0.320 |
A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). The maximum scores for joint space narrowing (JSN) in the hands was 104 and in the feet 48 for a total possible score of 0 to 152. A lower change from Baseline indicated a better score. Analysis of covariance model included baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.
| Score on a scale | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n= 266, 258) | 0.16 ± 0.121 | 0.19 ± 0.115 |
| Week 52 (n= 269, 264) | 0.45 ± 0.314 | 0.39 ± 0.297 |
| Week 104 (n= 215, 202) | 0.38 ± 0.218 | 0.70 ± 0.201 |
A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. The maximum erosion score in the hands was 98 and in the feet 42 for a total possible score of 0 to 140. A lower number change from Baseline indicated a better score.
| Score on a scale | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n=266,258) | 0.03 ± 0.077 | 0.15 ± 0.072 |
| Week 52 (n= 269,264) | -0.09 ± 0.125 | 0.25 ± 0.118 |
| Week 104 (n= 215,202) | -0.03 ± 0.169 | 0.26 ± 0.156 |
The percentage of participants who stopped treatment with tocilizumab due to remission.
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 52 (n=243,231) | 28.4 | 21.6 |
| Week 104 (n=243,229) | 53.1 | 47.6 |
Lack of Sufficient Therapeutic Response was defined as the patient not responding to the drug as expected.
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Percentage of Participants Who Withdrew Due to Lack of Sufficient Therapeutic Response | 1.8 | 4.7 |
Safety reasons were defined as adverse events, intercurrent illness or death. An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
| Percentage of participants | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Percentage of Participants Who Withdrew Due to Safety Reasons | 9.7 | 11.2 |
The RAQoL is a disease specific patient-reported outcome measure that determines the effect rheumatoid arthritis has on a patient's quality of life consisting of 30 questions that are answered either yes=1 or no=0 for a total possible score ranging from 0 (best) to 30 (worst). A negative change from Baseline indicated improvement.
| Score on a scale | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Week 24 (n=146,135) | -6.07 ± 8.005 | -5.19 ± 7.064 |
| Week 52 (n=132,111) | -7.28 ± 8.141 | -6.33 ± 7.691 |
| Week 104 (n=87,74) | -6.89 ± 8.691 | -5.24 ± 8.899 |
The Academic Medical Center (AMC) Linear Disability Score (ALDS) evaluates the participant's ability to perform activities of daily life consisting of 77 questions answered yes or no . The question difficulty and the patient's ability are arranged on a single hierarchical linear scale. ALDS scores range from 10 to 90 with a higher score representing higher functional status. A positive change from Baseline indicated improvement.
| Score on a scale | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Change From Baseline in Academic Medical Center (AMC) Linear Disability Scale (ALDS) | 2.42 ± 7.773 | 0.91 ± 2.099 |
ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]. Area under the curve for ACR response to Week 24 was averaged over study days. Analysis of covariance model includes treatment group, region and baseline DAS28 (≤ 5.5 and \> 5.5) as fixed factors.
| Score on a scale*day | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Area Under the Curve (AUC) From Baseline to Week 24 for ACR Response | 18.95 ± 4.220 | 13.74 ± 3.979 |
ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].Area under the curve for ACR response to Week 52 averaged over study days. Analysis of covariance model includes treatment group, region and baseline DAS28 (\<=5.5 and \>5.5) as fixed factors.
| Score on a scale*day | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Area Under the Curve (AUC) From Baseline to Week 52 for ACR Response | 30.48 ± 4.901 | 32.59 ± 4.611 |
The time in days from initial study drug treatment to tocilizumab remission that occurred when the patient discontinued treatment with tocilizumab.
| Days | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Time to Tocilizumab Remission | 645.0 (360 to 855) | 786.0 (351 to 829) |
The time in days from initial study drug treatment to drug free remission that occurred when the participant was able to discontinue tocilizumab, methotrexate/placebo and open label disease-modifying antirheumatic drugs (DMARDS).
| Days | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Time to Drug-Free Remission | NA (366 to 1121) | NA (365 to 1151) |
The time in days to a flare (recurrence of disease symptoms) after the patient discontinued treatment with tocilizumab.
| Days | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Time to Flare After Tocilizumab Remission | 113.0 (25 to 400) | 84.0 (1 to 415) |
The time in days from treatment discontinuation or remission to the restart of treatment.
| Days | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| Time to Restart of Treatment After Discontinuation/Remission | 113.0 (87.0 to 150.0) | 81.0 (58.0 to 91.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab + Methotrexate | — | 49/277 (17.7%) | 189/277 (68.2%) |
| Tocilizumab + Placebo | — | 48/276 (17.4%) | 179/276 (64.9%) |
| Event | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 0/277 | 3/276 |
| BronchopneumoniaInfections and infestations | 3/277 | 0/276 |
| ErysipelasInfections and infestations | 0/277 | 2/276 |
| Transient ischaemic attackNervous system disorders | 1/277 | 2/276 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/277 | 2/276 |
| Tendon ruptureInjury, poisoning and procedural complications | 0/277 | 2/276 |
| Acute myocardial infarctionCardiac disorders | 0/277 | 2/276 |
| Transaminases increasedInvestigations | 2/277 | 2/276 |
| Septic shockInfections and infestations | 2/277 | 0/276 |
| Cardiac failure congestiveCardiac disorders | 2/277 | 1/276 |
| Event | Tocilizumab + Methotrexate | Tocilizumab + Placebo |
|---|---|---|
| NasopharyngitisInfections and infestations | 43/277 | 40/276 |
| HypercholesterolemiaMetabolism and nutrition disorders | 34/277 | 33/276 |
| Alanine aminotransferase increasedInvestigations | 33/277 | 15/276 |
| Upper respiratory tract infectionInfections and infestations | 31/277 | 25/276 |
| Transaminases increaseInvestigations | 30/277 | 15/276 |
| Back painMusculoskeletal and connective tissue disorders | 29/277 | 21/276 |
| NauseaGastrointestinal disorders | 27/277 | 9/276 |
| Urinary tract infectionInfections and infestations | 23/277 | 18/276 |
| DiarrhoeaGastrointestinal disorders | 20/277 | 21/276 |
| HeadacheNervous system disorders | 18/277 | 21/276 |
Baseline measures are based on the Safety Population and include all randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | Tocilizumab + Methotrexate | Tocilizumab + Placebo | Total |
|---|---|---|---|
| Mean | 53.0 ± 13.40 | 53.6 ± 11.91 | 53.3 ± 12.67 |
| Sex: Female, Male(Participants) | Tocilizumab + Methotrexate | Tocilizumab + Placebo | Total |
|---|---|---|---|
| Female | 227 | 217 | 444 |
| Male | 50 | 59 | 109 |
Showing the first 100 of 137 sites across 20 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2009, a primary completion of Aug 2010 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate